Which companies are affected by this news?

Companies directly affected include: TCRX, ET.

Which industries does this news affect?

AlphaOS tracks industry-level impact for all major market events.

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

Q: What is the market impact of: TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation?

AlphaOS is tracking this market event: TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation.

July 10, 2026 · Updated Jul 10, 2026

Affected Companies

TCRX41

TScan Therapeutics, Inc.

AlphaOS aggregates and analyzes market news to extract structured investment intelligence. Content is for research and education only — not investment advice.